Abacus Medicine to acquire Pluripharm

13 July 2020

Denmark-headquartered Abacus Medicine is set to acquire Dutch pharmaceutical wholesaler Pluripharm Group.

The group is one of four leading wholesalers in the Netherlands with a full line of medicines, medical devices and services. Founded in 2004, Abacus Medicine is, according to its own estimates, the fastest-growing parallel trade company of original prescription pharmaceuticals in Europe.

The two companies believe the deal will allow Pluripharm to expand its offering to independent pharmacies and hospitals in the Netherlands, and ensure a high availability of medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK